标题
The evolving role of receptors as predictive biomarkers for metastatic breast cancer
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 19, Issue 2, Pages 121-138
出版商
Informa UK Limited
发表日期
2018-12-03
DOI
10.1080/14737140.2019.1552138
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract P3-08-16: ER, PR and HER2 biomarkers in UK and Irish clinical breast cancer testing: analysis of results from >168,000 patients
- (2018) A Dodson et al. CANCER RESEARCH
- Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
- (2018) MN Dickler et al. CANCER RESEARCH
- An update on first line therapies for metastatic breast cancer
- (2018) Palma Fedele et al. EXPERT OPINION ON PHARMACOTHERAPY
- Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
- (2018) Alexey A. Larionov Frontiers in Oncology
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Efficacy of Trastuzumab in Unselected Patients with HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis
- (2018) Elena Collovà et al. TUMORI
- Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
- (2017) M.J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases
- (2017) Gabriele Zoppoli et al. Journal of Translational Medicine
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
- (2017) Nick Beije et al. Molecular Oncology
- Prognostic and predictive biomarkers in breast cancer: Past, present and future
- (2017) Andrea Nicolini et al. SEMINARS IN CANCER BIOLOGY
- Molecular heterogeneity in breast cancer: State of the science and implications for patient care
- (2017) Rachel E. Ellsworth et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
- (2017) Takashi Takeshita et al. Translational Oncology
- Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
- (2017) Kazuhiro Araki et al. Breast Cancer
- An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
- (2017) Ariella B. Hanker et al. Cancer Discovery
- Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
- (2017) Takashi Takeshita et al. Oncotarget
- Fulvestrant in advanced breast cancer: evidence to date and place in therapy
- (2017) Katalin Boér Therapeutic Advances in Medical Oncology
- Correlation between IHC and FISH for HER2/neu assessment in patients with breast cancer
- (2017) S. Vigo et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
- (2016) S. Loibl et al. ANNALS OF ONCOLOGY
- Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less
- (2016) Angela Toss et al. BREAST
- Validated biomarkers: The key to precision treatment in patients with breast cancer
- (2016) Michael J. Duffy et al. BREAST
- ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
- (2016) Luca Gelsomino et al. BREAST CANCER RESEARCH AND TREATMENT
- Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
- (2016) Anna Nordenskjöld et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract OT1-02-02: The DETECT study program – Personalized treatment in metastatic breast cancer based on circulating tumor cells
- (2016) A Schramm et al. CANCER RESEARCH
- Tumor Heterogeneity--A 'Contemporary Concept Founded on Historical Insights and Predictions
- (2016) D. R. Welch CANCER RESEARCH
- Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer
- (2016) J S Carroll EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
- (2016) Alessandra Fabi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Metastatic breast cancer: The Odyssey of personalization
- (2016) A. Sonnenblick et al. Molecular Oncology
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- ESR1 -Amplification-Associated Estrogen Receptor α Activity in Breast Cancer
- (2016) Frederik Holst et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
- (2016) Xiuwen Guan et al. Oncotarget
- Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
- (2016) Debora de Melo Gagliato et al. Oncotarget
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies
- (2016) Dominic A. Pearce et al. Scientific Reports
- Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1
- (2015) Daniela Furrer et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors
- (2015) Camille Petrau et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Targeting HER2 for the Treatment of Breast Cancer
- (2015) Mothaffar F. Rimawi et al. Annual Review of Medicine
- RAD1901
- (2015) Fiona Garner et al. ANTI-CANCER DRUGS
- Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer
- (2015) Savas D. Soysal et al. BREAST CANCER RESEARCH AND TREATMENT
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SEOM clinical guidelines in metastatic breast cancer 2015
- (2015) J. Gavilá et al. Clinical & Translational Oncology
- ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
- (2015) D. Chu et al. CLINICAL CANCER RESEARCH
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
- (2015) P. Wang et al. CLINICAL CANCER RESEARCH
- Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer
- (2015) D. S. Guttery et al. CLINICAL CHEMISTRY
- A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer
- (2015) Ting Wang et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer
- (2015) David Sefrioui et al. INTERNATIONAL JOURNAL OF CANCER
- Intrinsic Subtypes,PIK3CAMutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
- (2015) Katherine L. Pogue-Geile et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2015) Catherine Van Poznak et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
- (2015) Andiliy Lai et al. JOURNAL OF MEDICINAL CHEMISTRY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Endocrine resistance in breast cancer – An overview and update
- (2015) Robert Clarke et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Progesterone receptor modulates ERα action in breast cancer
- (2015) Hisham Mohammed et al. NATURE
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Clinical management of breast cancer heterogeneity
- (2015) Dimitrios Zardavas et al. Nature Reviews Clinical Oncology
- Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics
- (2015) H. Gilbert Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials
- (2015) M. Hicks et al. ONCOLOGIST
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
- (2015) Takashi Takeshita et al. Translational Research
- Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ
- (2015) Yasuaki Sagara et al. JAMA Surgery
- ESR1 Amplification is Rare in Breast Cancer and is Associated with High Grade and High Proliferation: A Multiplex Ligation-Dependent Probe Amplification Study
- (2015) Cathy B. Moelans et al. Analytical Cellular Pathology
- Molecular Differences between Ductal CarcinomaIn Situand Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study
- (2015) Cathy B. Moelans et al. Analytical Cellular Pathology
- Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research
- (2014) P. K. Grover et al. ANNALS OF ONCOLOGY
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
- (2014) F. Cardoso et al. ANNALS OF ONCOLOGY
- Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
- (2014) Jessica Salmen et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
- (2014) IA Mayer et al. CANCER RESEARCH
- Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
- (2014) Y. Wang et al. CANCER RESEARCH
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool
- (2014) J. F. Huggett et al. CLINICAL CHEMISTRY
- Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for Minimization
- (2014) H. Do et al. CLINICAL CHEMISTRY
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated UK Recommendations for HER2 assessment in breast cancer
- (2014) Emad A Rakha et al. JOURNAL OF CLINICAL PATHOLOGY
- A community effort to assess and improve drug sensitivity prediction algorithms
- (2014) James C Costello et al. NATURE BIOTECHNOLOGY
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer
- (2014) Z. Eroglu et al. ONCOLOGIST
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Treatment of HER2-positive breast cancer
- (2013) Maria Cristina Figueroa-Magalhães et al. BREAST
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
- (2013) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?
- (2013) K. Pantel et al. CANCER RESEARCH
- HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact
- (2013) Natalie H. Turner et al. CANCER TREATMENT REVIEWS
- HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
- (2013) Susan Dent et al. CANCER TREATMENT REVIEWS
- HER2 testing: Current status and future directions
- (2013) Edith A. Perez et al. CANCER TREATMENT REVIEWS
- Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
- (2013) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
- (2013) Gaetano Aurilio et al. EUROPEAN JOURNAL OF CANCER
- Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens
- (2013) Andrew G. Hadd et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Use of SERMs for treatment in postmenopausal women
- (2013) JoAnn V. Pinkerton et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Liquid biopsy: monitoring cancer-genetics in the blood
- (2013) Emily Crowley et al. Nature Reviews Clinical Oncology
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- The Life History of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Breast cancer intratumor genetic heterogeneity: causes and implications
- (2012) Charlotte KY Ng et al. Expert Review of Anticancer Therapy
- ESR1 amplification in breast cancer: controversy resolved?
- (2012) Donna G Albertson JOURNAL OF PATHOLOGY
- Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?
- (2012) Lauren T. Greer et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- (2012) Hyesil Seol et al. MODERN PATHOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of ultra-rare mutations by next-generation sequencing
- (2012) M. W. Schmitt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Tumor Metastasis: Molecular Insights and Evolving Paradigms
- (2011) Scott Valastyan et al. CELL
- Tumour seeding following percutaneous needle biopsy: The real story!
- (2011) E.G. Robertson et al. CLINICAL RADIOLOGY
- Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer
- (2011) D. Hompes et al. EJSO
- Gene amplification of ESR1 in breast cancers-fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study
- (2011) Akishi Ooi et al. JOURNAL OF PATHOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Detection and quantification of rare mutations with massively parallel sequencing
- (2011) I. Kinde et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1
- (2011) Anita K. Dunbier et al. PLoS Genetics
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
- (2010) Ruth E. Board et al. BREAST CANCER RESEARCH AND TREATMENT
- Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
- (2010) J. Sperinde et al. CLINICAL CANCER RESEARCH
- Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease
- (2010) Rena Callahan et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis
- (2010) Vanya Van Belle et al. JOURNAL OF CLINICAL ONCOLOGY
- Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis
- (2010) Evangelos Tsiambas et al. MEDICAL ONCOLOGY
- Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes
- (2010) Cathy B Moelans et al. MODERN PATHOLOGY
- Genomic rearrangements in inherited disease and cancer
- (2010) Jian-Min Chen et al. SEMINARS IN CANCER BIOLOGY
- Massively Parallel Sequencing: The Next Big Thing in Genetic Medicine
- (2009) Tracy Tucker et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR
- (2009) Anieta M. Sieuwerts et al. BREAST CANCER RESEARCH AND TREATMENT
- Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
- (2009) Shuzhen Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Oestrogen receptor splice variants in the pathogenesis of disease
- (2009) Siân E. Taylor et al. CANCER LETTERS
- Estrogen receptor α geneESR1amplification may predict endocrine therapy responsiveness in breast cancer patients
- (2009) Saori Tomita et al. CANCER SCIENCE
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- Genomic rearrangements in BRCA1 and BRCA2: a literature review
- (2009) Ingrid Petroni Ewald et al. GENETICS AND MOLECULAR BIOLOGY
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer seeding associated with core needle biopsies: A systematic review
- (2009) Fabienne Liebens et al. MATURITAS
- Complex landscapes of somatic rearrangement in human breast cancer genomes
- (2009) Philip J. Stephens et al. NATURE
- Mutation Detection by Real-Time PCR: A Simple, Robust and Highly Selective Method
- (2009) John Morlan et al. PLoS One
- Prognostic factors in 1038 women with metastatic breast cancer
- (2008) R. Largillier et al. ANNALS OF ONCOLOGY
- The Genomic Heritage of Lymph Node Metastases: Implications for Clinical Management of Patients with Breast Cancer
- (2008) Tyson E. Becker et al. ANNALS OF SURGICAL ONCOLOGY
- Molecular profiles of progesterone receptor loss in human breast tumors
- (2008) Chad J. Creighton et al. BREAST CANCER RESEARCH AND TREATMENT
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
- Absence of ESR1 amplification in a series of breast cancers
- (2008) José Adélaïde et al. INTERNATIONAL JOURNAL OF CANCER
- Next-generation DNA sequencing
- (2008) Jay Shendure et al. NATURE BIOTECHNOLOGY
- ESR1 gene amplification in breast cancer: a common phenomenon?
- (2008) Anne Vincent-Salomon et al. NATURE GENETICS
- ESR1 gene amplification in breast cancer: a common phenomenon?
- (2008) Jorge S Reis-Filho et al. NATURE GENETICS
- Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?”
- (2008) Frederik Holst et al. NATURE GENETICS
- Conflicting evidence on the frequency of ESR1 amplification in breast cancer
- (2008) Donna G Albertson NATURE GENETICS
- ESR1 gene amplification in breast cancer: a common phenomenon?
- (2008) Lindsay A Brown et al. NATURE GENETICS
- ESR1 gene amplification in breast cancer: a common phenomenon?
- (2008) Hugo M Horlings et al. NATURE GENETICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started